Restricted joint range of motion in patients with MPS II: Correlation with height, age and functional status

Acta Paediatrica, International Journal of Paediatrics

Volumn 101, Issue 4, 2012, Pages

  Marucha, Jolanta ^a   Jurecka, Agnieszka ^a,b   Syczewska, Maågorzata ^a   Rózdzynska Swia̧tkowska, Agnieszka ^a   Tylki Szymańska, Anna ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Activity of daily living; Height; Hunter syndrome; Mucopolysaccharidosis type II; Range of motion

Indexed keywords

ADOLESCENT; ADULT; AGE; ARTICLE; BODY HEIGHT; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; GONIOMETRY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUNTER SYNDROME; JOINT MOBILITY; MALE; PRIORITY JOURNAL; RANGE OF MOTION; SHOULDER;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGE FACTORS; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; MALE; MUCOPOLYSACCHARIDOSIS II; RANGE OF MOTION, ARTICULAR; SHOULDER JOINT; YOUNG ADULT;

EID: 84858080288     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2011.02522.x     Document Type: Article

References (24)

1. Neufeld EF, Muenzer J,. The mucopolysaccharidoses. In:, Scriver CR, Beaudet AL, Sly WS, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill, 2001.
2. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V, et al., Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008; 121: e377-86. (Pubitemid 351198459)
3. Hinek A, Wilson SE,. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 2000; 156: 925-38. (Pubitemid 30626951)
4. Pastores GM, Meere PA,. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol 2005; 17: 70-8. (Pubitemid 40075651)
5. Simonaro CM, D'Angelo M, He X, Eliyahu E, Shtraizent N, Haskins ME, et al., Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol 2008; 172: 112-22. (Pubitemid 351186373)
6. Simonaro CM, D'Angelo M, Haskins ME, Schuchman EH,. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res 2005; 57: 701-7. (Pubitemid 40578042)
7. Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH,. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 2010; 107: 222-7.
8. Simonaro CM, Haskins ME, Schuchman EH,. Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest 2001; 81: 1319-28. (Pubitemid 32911980)
9. Buckup K,. Klinische Tests an Knochen Gelenken und Muskeln. Stuttgart: Thieme Georg Verlag, 1995: 10-15.
10. Gerhardt JJ, Rondinelli RD,. Goniometric techniques for range-of-motion assessment. Phys Med Rehabil Clin N Am 2001; 12: 507-27. (Pubitemid 32652538)
11. Carter DR,. Mechanical loading history and skeletal biology. J of Biomechanics 1987; 20: 1095-109.
12. Doorenbosch CA, Harlaar J, Veeger DH,. The globe system: an unambiguous description of shoulder positions in daily life movements. J Rehabil Res Dev 2003; 40: 147-55. (Pubitemid 36532292)
13. Zembaty A,. Kinezyterapia. Kraków: Kasper, 2002: 62-73, 239- 43.
14. Norato DYJ, Giovanetti DF,. MPS I Registry health assessment questionnaire. 9th International Symposium on Mucopolysaccharidosis and Related Diseases. Venice, 2006.
15. Zimmermann B III, Lally EV, Sharma SC, Schoen FJ, Kaplan SR,. Severe aortic stenosis in systemic lupus erythematosus and mucopolysaccharidosis type II (Hunter's syndrome). Clin Cardiol 1988; 11: 723-5.
16. Morini SR, Steiner CE, Gerson LB,. Mucopolysaccharidosis type II: skeletal-muscle system involvement. J Pediatr Orthop B 2010; 19: 313-7.
17. Link B, de Camargo Pinto LL, Giugliani R, Wraith JE, Guffon N, Eich E, et al., Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop Rev (Pavia) 2010; 2: e16.
18. Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al., A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007; 90: 171-80. (Pubitemid 46108607)
19. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al., Enzyme-replacement therapy in mucopolysaccharidosis I. N Eng J Med 2001; 344: 182-8. (Pubitemid 32064139)
20. Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska B,. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis 2010; 33: 151-7.
21. Rozdzynska A, Tylki-Szymanska A, Jurecka A, Cieslik J,. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta Paediatr 2011; 100: 456-60.
22. Morton L,. Medical Bibliography. 5th ed. Bookfield: Scolar Press/Ashgate Pub, 1991: ISBN: 9780859678971.
23. Dega W,. Ortopedia i Rehabilitacja. Warszawa: PZWL, 1983: 17-35.
24. Schmitt HP,. Changes in the voluntary muscles and the peripheral nerves in an autopsy case of MPS type II (Hunter). Neuropediatrics 1981; 12: 83-91. (Pubitemid 11191637)